

Axxima Pharmaceuticals AG

[View the current Axxima Pharmaceuticals AG Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/1150-Axxima+Pharmaceuticals+AG.html)

(<http://www.bioportfolio.com/bi corporate/1150-Axxima+Pharmaceuticals+AG.html>)

Contact Details:

Am Klopferspitz 19

Martinsried

Bavaria

D-82152

Germany

Tel: +49 (0) 89 - 740 165 - 0

Fax: +49 (0) 89 - 740 165 - 20

Email:

Axxima Pharmaceuticals AG (formerly VirGene) is the leader in the application of pathogen-host signal transduction intervention. The company develops proprietary drugs that are based on Axxima's revolutionary approach to generate a Signal Transduction Firewall (STF) against pathogens. Axxima's business strategy is to pursue the highly desirable area of anti-infective drug discovery from beginning to end, from target identification to drug development, making it a small pharmaceutical company rather than a traditional platform-based biotechnology startup. Axxima has developed a technology platform directed towards the identification of "critical" interaction points between a pathogen and target cells in the host. Axxima is developing small molecule drugs to interfere at these critical interaction points, thus blocking the pathogen's manipulation of the host cell and leaving the pathogen without the tools with which to establish itself in the host.

Recent Publications by Axxima Pharmaceuticals AG:



- [Advances in anti-viral therapeutics.](#)

Hepatitis C virus (HCV) and HIV infections are of high economical... 14th April, 2006

Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, D-81377 Munich, Germany.- Expert Opin Investig Drugs. 2005 Mar;14(3):343-8. ([DOI Direct Link](#))

- [Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.](#)

Knowledge about molecular drug action is critical for the development of... 5th October, 2005

Axxima Pharmaceuticals AG, Munich, Germany.- Cancer Res. 2005 Aug 1;65(15):6919-26. ([DOI Direct Link](#))

- [Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay.](#)

- The human cytomegalovirus (HCMV) protein kinase pUL97 represents an...* 19th August, 2005
Axxima Pharmaceuticals AG, Munich, Germany.- J Biomol Screen. 2005 Feb;10(1):36-45. ([DOI Direct Link](#))
- [Host cell targets in HCV therapy: novel strategy or proven practice?](#)
The development of novel antiviral drugs against hepatitis C is a... 12th August, 2005
Axxima Pharmaceuticals- Antivir Chem Chemother. 2005;16(2):69-90.
 - [Chemical proteomic analysis reveals alternative modes of action for pyrido\[2,3-d\]pyrimidine kinase inhibitors.](#)
Small molecule inhibitors belonging to the pyrido[2,3-d]pyrimidine class... 21st June, 2005
Axxima Pharmaceuticals AG, 81377 Munchen, Germany.- Mol Cell Proteomics. 2004 Dec;3(12):1181-93. Epub 2004 Oct 8. ([DOI Direct Link](#))
 - [Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells.](#)
There is great medical need to develop novel therapies for treatment of... 20th April, 2005
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.- J Biol Chem. 2005 Mar 11;280(10):8831-41. Epub 2004 Dec 28. ([DOI Direct Link](#))
 - [Interplay between mycobacteria and host signalling pathways.](#)
Some protein kinases are known to acquire resistance to selective small... 23rd March, 2005
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.- Nat Rev Microbiol. 2004 Mar;2(3):189-202. ([DOI Direct Link](#))
 - [Screening assay for the identification of deoxyhypusine synthase inhibitors.](#)
The 1st step in the posttranslational hypusine... 16th March, 2005
Department of Assay Development and Screening, Axxima Pharmaceuticals AG,- J Biomol Screen. 2004 Aug;9(5):434-8. ([DOI Direct Link](#))
 - [NF-kappaB activation can mediate inhibition of human cytomegalovirus replication.](#)
The activation of NF-kappaB has long been considered a positive factor for... 10th March, 2005
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.- J Gen Virol. 2005 Feb;86(Pt 2):285-95. ([DOI Direct Link](#))
 - [Cellular targets of gefitinib.](#)
Targeted inhibition of protein kinases with small molecule drugs has... 3rd March, 2005
Axxima Pharmaceuticals AG, Munich, Germany.- Cancer Res. 2005 Jan 15;65(2):379-82.
 - [Strategies to overcome resistance to targeted protein kinase inhibitors.](#)
Selective inhibition of protein tyrosine kinases is gaining importance as... 4th February, 2005
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munchen, Germany.- Nat Rev Drug Discov. 2004 Dec;3(12):1001-10. ([DOI Direct Link](#))
 - [Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.](#)
Some protein kinases are known to acquire resistance to selective small... 8th January, 2005
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.- Chem Biol. 2004 May;11(5):691-701. ([DOI Direct Link](#))
 - [Evaluation of kinase inhibitor selectivity by chemical proteomics.](#)
Small-molecule inhibitors of protein kinases constitute a novel class of... 16th December, 2004
Axxima Pharmaceuticals- Assay Drug Dev Technol. 2004 Apr;2(2):215-24. ([DOI Direct Link](#))
 - [Proteomic analysis of kinase inhibitor selectivity and function.](#)
Small molecule inhibitors of protein kinases have become highly popular... 29th September, 2004
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, Munchen, Germany.- Cell Cycle. 2004 Apr;3(4):393-5. Epub 2004 Apr 1.
 - [Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.](#)
Bisindolylmaleimide compounds such as GF109203X are potent inhibitors of... 4th September, 2004
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.- Mol Cell Proteomics. 2004 May;3(5):490-500. Epub 2004 Feb 9. ([DOI Direct Link](#))

- [AGS: Non-drug Therapies Ease Insomnia in Elderly](#)
Consultant Live: Jan 1 2009 9:33AM Matching: pharmaceuticals ag
- [Bangladesh Pharmaceuticals and Healthcare Report Q4 2008](#)
Mindbranch: Jan 1 2009 12:16AM Matching: pharmaceuticals ag
- [2nd UPDATE: Akorn Shrs Surge On FDA Drug Approvals AKRX](#)
Wall Street Journal Online: Dec 31 2008 7:51PM Matching: pharmaceuticals ag
- [Salix Pharmaceuticals Ltd announces complete response letter for Balsalazide Tablet from FDA](#)
M2: Dec 31 2008 6:10AM Matching: pharmaceuticals ag
- [Early surgical intervention is safe for patients on anti-platelet medication](#)
Orthopedics Today: Dec 30 2008 12:47PM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
Pharma Live: Dec 30 2008 2:30AM Matching: pharmaceuticals ag
- [Salix Pharmaceuticals Ltd announces complete response letter for Balsalazide Tablet from FDA](#)
TradingMarkets: Dec 30 2008 3:56PM Matching: pharmaceuticals ag
- [Wyeth :New vaccine protects against the 13 most prevalent serotypes associated with serious pneumococcal disea](#)
AME Info: Dec 30 2008 8:58AM Matching: pharmaceuticals ag
- [AstraZeneca Submits sNDA for NEXIUM\(R\) for the Short-Term Treatment of GERD in Infants 0 to 1 Year Old](#)
Rehab Manegement: Dec 27 2008 10:17AM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
DiGiTAL50: Dec 25 2008 6:57AM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
Houston Chronicle: Dec 25 2008 6:04AM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
Earthtimes.org: Dec 24 2008 11:57PM Matching: pharmaceuticals ag
- [SARcode completes phase 1 trial of compound for ocular inflammation](#)
OSN Super Site: Dec 25 2008 6:00PM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
Business Wire: Dec 24 2008 9:05PM Matching: pharmaceuticals ag
- [CCHR Says New Mental Health Study on College-Aged Students Misleading](#)
Business Wire via Yahoo!: Dec 24 2008 9:15PM Matching: pharmaceuticals ag

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

